At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis receiving the investigational IL-13 inhibitor lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company announced April 11 at the 4th Annual Revolutionizing Atopic Dermatitis Conference.
Eli Lilly announced the success of the global health care company’s clinical trial on lebrikizumab as a treatment for people diagnosed with moderate to severe atopic dermatitis (AD).
Shares of ASLAN Pharmaceuticals rose more than 83 percent after the company announced positive preliminary data in an atopic dermatitis study.
A little more than a week after announcing plans to acquire Ra Pharmaceutical for $2.1 billion, UCB’s psoriasis drug bimekizumab met all endpoints in the first of three Phase III studies.
The European Commission approved Dupixent (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide, who are inadequately controlled with high dose inhaled corticosteroid plus another medicinal product for maintenance treatment.
On Sept. 11, 2017, Regeneron Pharmaceuticals and Sanofi announced positive data for its Phase III LIBERTY ASTHMA QUEST trial of Dupixent (dupilumab) in asthma. Investors and analysts do not seem to agree on whether dupilumab is on its way to being one of the biggest blockbuster drugs in the last two years, or if it’s the most overhyped drug on the market.